Samuel
Senior Member (Voting Rights)
> Public comments received in response to a Request for Information from the NANDS Council Working Group for ME/CFS Research are now available: https://www.ninds.nih.gov/node/18206
				
			
			
				Last edited: 
			
		
	
								
								
									
	
								
							
							I have recently done this exercise, together with Derya Unutmaz and Maureen Hanson, for UK MRC as an advisory board so I thought I would just offer some bullet points along the same lines here. Vicky Whittemore knows that I am a retired biomedical scientist with a major interest in ME research as a sort of 'disinterested uncle'.
Chris Ponting has convinced me that pushing genetic studies is worth doing. We need to draw on the really big datasets (hundreds of thousands or more if possible for 'first pass' trawling. We also need to verify using smaller carefully recruited population based cohorts like the UK ME biobank cohort. I think there are likely to be serious confounding ascertainment factors in cohorts that are not truly population representative and I am not yet convinced that people are aware just how serious they are. But I don't think they preclude getting a valid answer with careful methodology.
The other idea is something that came from a 'citizen scientist' patient. The key clinical problem in ME/CFS is exertion intolerance. I think we need to be able to measure that objectively. I think there is an analogy with the inability to move rapidly and smoothly in Parkinsonism. The neurologists have made progress in documenting this with actimetry - including describing on-off phenomena. Actimetry in ME/CFS has mostly looked at just quantity of activity but I think it needs to be used to look at PATTERNS of impaired activity so that these can be tracked objectively over long periods. The technical term for this is apparently 'motor fatigue'. That is to say not a sense of fatigue but a behavioural pattern that can be studied objectively. Only when we understand these patterns will we know what we are trying to explain. I think it very likely that if we really knew what the activity deficit was we would know we are not looking for a metabolic defect, for instance.
That response makes it sound like we are a long way away from anything that will help us. Glad to see the input but it seems like we are looking at a long road ahead. Any thoughts? Also hundreds of thousands.. We don't have info on hundreds of thousands of patients and unlikely will for another century considering doctors can't even diagnose ME.Hopefully they will be making an effort to group responses into broad categories, to make it easy to gain an overview.
Although the responses have, where needed, been anonymised, I think I could probably guess who might have submitted this.
I think we are undoubtedly in the early stages of getting any proper level of funding from government bodies. Although we would like to see far more from the NiH at least they are providing some, and the amount that they provide is still far far greater than the UK and EU does. However, the quote does hint that perhaps the UK's MRC is starting to take it more seriously as a topic as not only did they form an advisory board, but they also recruited Unutmaz, Hanson and, I suspect, @Jonathan Edwards to be part of it. So it suggests that some progress is being made, but as to when that will translate in to something substantially beneficial for us patients - I would be surprised if it was less than a decade.That response makes it sound like we are a long way away from anything that will help us. Glad to see the input but it seems like we are looking at a long road ahead. Any thoughts?
It's true that we don't have data on that many ME/CFS patients at the moment. My guess would be that, with an international effort, it could be possible, but it would require time, education (of officials and patients) and money.Also hundreds of thousands.. We don't have info on hundreds of thousands of patients and unlikely will for another century considering doctors can't even diagnose ME.
It is impossible to sift through those comments and not conclude that everything is yet to be done, that we are still firmly at step 1 and absolutely nothing of value was accomplished in the 3 decades lost to the psychosocial ideology. An entire generation, tens of millions, wasted on the pipe dream of pseudoscientific delusion. Few tyrants in history have ever managed to destroy this many lives so effectively and without resistance.> Public comments received in response to a Request for Information from the NANDS Council Working Group for ME/CFS Research are now available: https://www.ninds.nih.gov/node/18206
Find MDs who have been afflicted so they can speak the medical lingo to researchers & be part of a) changing mindsets and b) collaborating on a solution
From a systems science point of view, I believe the epidemiology of ME/CFS needs a major update. ME/CFS research will not likely be fully funded until the general public become worried about the growth rate of the condition. This is really a big deal in my opinion because nobody is talking about the role of epidemiology in the sequence of power in getting funding. Here is the model:Competent Epidemiology => Public Worries => Medical Engagement (calls for action, etc) => Pressure on Elected Officials => Congressional Funding Response => NIH and related agency cooperation => Increased Funding => Increased Research Activity => Better Clinical Management => SolutionsCurrently the missing link is 'public worries'. We are a worried patient community, but patient worries do not lead to significant medical engagement or pressure on public officials. We are just another special interest group to them. That is not adequate. Think of the AIDS response, how the public fear was a critical factor, that response was not just a few worried patients or patient associations. We are missing the big splash in public awareness, and I believe a competent epidemiological study could trigger that. Yes, this is a long game and I know people want quick studies and answers, I want those too, but for the major funding we need, we have to play the long game well, not just the short game.
That response makes it sound like we are a long way away from anything that will help us. Glad to see the input but it seems like we are looking at a long road ahead. Any thoughts? Also hundreds of thousands.. We don't have info on hundreds of thousands of patients and unlikely will for another century considering doctors can't even diagnose ME.
During the NIH conference Dr. Maureen Hanson challenged Dr. Francis Collins to fund ME as much as HIV. She said; ‘You lose your life to this disease.’
It suggests that there is a major genetic element in ME that is not a simple Mendelian issue
Maureen Hanson's words were so powerful, certainly to the patient population.From another comment:
An applause for Dr Hanson!
What does not a simple Mendelian issue mean?
Is this something that the UK MEbiobank could take on IF we could find an interested researcher and funding?Objective measures of post exertional malaise
Just wanted to highlight the idea submitted by the famous anonymous author:
The other idea is something that came from a 'citizen scientist' patient. The key clinical problem in ME/CFS is exertion intolerance. I think we need to be able to measure that objectively. I think there is an analogy with the inability to move rapidly and smoothly in Parkinsonism. The neurologists have made progress in documenting this with actimetry - including describing on-off phenomena. Actimetry in ME/CFS has mostly looked at just quantity of activity but I think it needs to be used to look at PATTERNS of impaired activity so that these can be tracked objectively over long periods. The technical term for this is apparently 'motor fatigue'. That is to say not a sense of fatigue but a behavioural pattern that can be studied objectively. Only when we understand these patterns will we know what we are trying to explain. I think it very likely that if we really knew what the activity deficit was we would know we are not looking for a metabolic defect, for instance.
This is a great idea. The challenge, of course, is to identify the characteristic patterns. It would be necessary to validate the patterns against self-reported PEM from patients, and also compare with the patterns of sick controls.
Well, I think the potential is there but as you state it would need an interested, and skilled in the relevant area, researcher with the time and funding. I do know that all in the CureME team are very busy with various projects already.Is this something that the UK MEbiobank could take on IF we could find an interested researcher and funding?
Objective measures of post exertional malaise
Just wanted to highlight the idea submitted by the famous anonymous author:
The other idea is something that came from a 'citizen scientist' patient. The key clinical problem in ME/CFS is exertion intolerance. I think we need to be able to measure that objectively. I think there is an analogy with the inability to move rapidly and smoothly in Parkinsonism. The neurologists have made progress in documenting this with actimetry - including describing on-off phenomena. Actimetry in ME/CFS has mostly looked at just quantity of activity but I think it needs to be used to look at PATTERNS of impaired activity so that these can be tracked objectively over long periods. The technical term for this is apparently 'motor fatigue'. That is to say not a sense of fatigue but a behavioural pattern that can be studied objectively. Only when we understand these patterns will we know what we are trying to explain. I think it very likely that if we really knew what the activity deficit was we would know we are not looking for a metabolic defect, for instance.
This is a great idea. The challenge, of course, is to identify the characteristic patterns. It would be necessary to validate the patterns against self-reported PEM from patients, and also compare with the patterns of sick controls.
Objective measures of post exertional malaise
Yes, e.g. controls with depression or anxiety (again, not only PEM but also fatigabuility) --The challenge, of course, is to identify the characteristic patterns. It would be necessary to validate the patterns against self-reported PEM from patients, and also compare with the patterns of sick controls.
